Stifel Maintains Buy on Revolution Medicines, Raises Price Target to $230
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Stifel analyst Laura Prendergast maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $215 to $230.
Stifel analyst Laura Prendergast maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $215 to $230.